{'fraction_non_alphanumeric': 0.030973451327433628, 'fraction_numerical': 0.0022123893805309734, 'mean_word_length': 5.4714285714285715, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preoperative therapy: what, when and for whom?

Nowadays, early breast cancer is regarded as a systemic disease with a loco-regional component. Thus, systemic treatment comprises a fundamental component of the treatment of patients suffering from this disease. Preor postoperative administration of cytotoxic therapy has similar efficacy in this setting [1]. Current understanding of the target population, aims as well as schedules, will be discussed.